Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights

Siu Hin Wan, Horng H. Chen

Research output: Contribution to journalReview articlepeer-review


Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.

Original languageEnglish (US)
Article number40
JournalCurrent Cardiovascular Risk Reports
Issue number8
StatePublished - Aug 25 2015


  • Diastolic dysfunction
  • Echocardiography
  • Heart failure epidemiology
  • Heart failure treatment
  • Heart failure with preserved ejection fraction
  • Preclinical diastolic dysfunction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights'. Together they form a unique fingerprint.

Cite this